Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725270 · ClinicalTrials.gov registry record · Phase 2
Treatment of Schizoaffective Disorder Using Mifepristone
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00725270: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00725270 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725270, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
Interventions
- DRUG Mifepristone
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1998-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725270
The ClinicalTrials.gov registry entry for NCT00725270 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mifepristone is the first listed.
NCT00725270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725270 about?
NCT00725270 is a clinical study titled "Treatment of Schizoaffective Disorder Using Mifepristone". This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
What is the current status of trial NCT00725270?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1998-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00725270?
The interventions under investigation include: Mifepristone (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT00725270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.